source
- FDA signals openness to innovative approaches for psychedelic drug developmentFDA officials said the agency is open to novel, innovative approaches to the clinical development of psychedelic drugs, citing the worsening mental health crisis in the United States. The agency’s…
- Boehringer Ingelheim pauses Phase 1 study of oral candidate BI 3031185 after safety eventBoehringer Ingelheim has placed a Phase 1 study of its oral candidate BI 3031185 on hold after a safety event was identified. The trial, run in Japan with healthy volunteers, was assessing tolerab…